In a groundbreaking endeavor that bridges neurology, sleep medicine, and immunology, researchers at the Yale School of Medicine have officially launched a major multi-center clinical trial. The study is designed to investigate whether adalimumab—a widely prescribed anti-inflammatory medication known commercially as Humira—can successfully delay or entirely prevent the onset of Parkinson’s disease in individuals identified as being at high risk.
Spearheaded by Jesse Cedarbaum, MD, professor of neurology, and David Hafler, MD, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale, the trial marks a historic milestone. It represents the first clinical study of its kind to test whether a targeted pharmacological intervention can arrest the neurological cascade before the emergence of classic motor symptoms.
The rationale behind the trial rests on a critical window of opportunity that opens years, and sometimes decades, before a formal Parkinson’s diagnosis. For many patients, the earliest warning signs manifest not as tremors or rigidity, but as a specialized sleep disturbance. Known as rapid eye movement sleep behavior disorder, or RBD, this condition causes individuals to physically and sometimes violently act out their vivid dreams because the brain’s normal paralysis mechanism fails during REM sleep. Clinical data shows that an alarming percentage—up to 90% of individuals with isolated RBD—will eventually progress to develop Parkinson’s disease or a related neurodegenerative brain disorder, making them an ideal population for early preventative intervention.
What is REM sleep behavior disorder?
To understand the trajectory of the new research, clinicians emphasize the unique nature of rapid eye movement sleep. During normal REM sleep, vivid dreaming occurs while the eyes dart rapidly behind closed lids. Simultaneously, a healthy brain engages a neurochemical mechanism that paralyzes the skeletal muscles from the neck down, preventing the sleeper from acting out physical movements. Observers can witness a milder version of this suppression in sleeping domestic animals, such as a puppy twitching or whimpering while its motor output is heavily restrained.
However, in patients diagnosed with RBD, this critical protective paralysis mechanism breaks down entirely. The consequences can be hazardous for both the patients and their bed partners. Individuals have been documented kicking, punching, falling out of bed, or even engaging in routine, conscious-seeming behaviors like sitting up to smoke a cigarette or drink a cup of coffee while fast asleep.
While some instances of RBD can be triggered by external factors such as specific antidepressant medications, many cases arise spontaneously without a clear external trigger. Termed idiopathic or isolated RBD, these unprovoked cases carry a staggering prognosis. According to Dr. Cedarbaum, patients who seek medical evaluation for isolated RBD face a conversion rate of approximately 6% per year toward Parkinson’s disease or related synucleinopathies like dementia with Lewy bodies, with the transition unfolding across a 15- to 20-year window.
Emerging scientific consensus indicates that the pathological process driving this transformation frequently originates outside the central nervous system, often beginning in the gastrointestinal tract. All human nerve cells contain a normal protein called alpha-synuclein. In the post-mortem brains of individuals who suffered from Parkinson’s disease, scientists consistently find dense aggregates of this protein, commonly referred to as Lewy bodies. Researchers have likewise detected pathological clumps of alpha-synuclein within the nerve cells of the gut.
From the intestines, these protein aggregates can propagate toward the brain through several anatomical pathways, most notably via the vagus nerve, which establishes a direct connection between the gastrointestinal tract and the central nervous system. Aggregates can also initiate within the olfactory bulb, providing a clear explanation for why many Parkinson’s patients report an early and permanent loss of their sense of smell.
Once these protein clusters reach the brainstem, alpha-synuclein begins a progressive migration from one nerve cell to the next. Among the earliest neuronal populations affected are the cells responsible for regulating muscle paralysis during sleep, directly precipitating the onset of RBD. As the synuclein pathology continues its ascent into the mid-brain, it invades a specialized region known as the substantia nigra, which forms part of the basal ganglia—a complex network of structures governing voluntary movement.
The substantia nigra normally produces and transmits a vital neurotransmitter called dopamine into the broader basal ganglia network. Dr. Cedarbaum illustrates the mechanism using a mechanical analogy, describing the basal ganglia as the brain’s gearbox and dopamine as the lubricating oil. When alpha-synuclein damages the cells within the substantia nigra, they fail to produce adequate dopamine. Without this crucial lubrication, physical movement becomes progressively slow, rigid, and tremulous.
While current medical therapies, such as levodopa, are remarkably effective at replenishing dopamine levels and suppressing the motor symptoms of Parkinson’s disease, they do nothing to halt the underlying trajectory of alpha-synuclein. The protein continues its slow climb through the brain over decades, eventually reaching regions responsible for cognitive function and triggering dementia. Consequently, the appearance of RBD acts as a biological alarm bell, signaling that a destructive pathological process is already well underway and providing clinicians with a vital window for early intervention.
Inflammation and Parkinson’s disease
The physical spread of misfolded alpha-synuclein, however, represents only part of the pathological puzzle. Dr. Cedarbaum spent much of his distinguished career searching for viable interventions to protect dopamine-producing nerve cells from cell death. He was preparing for retirement when he was approached by Dr. Hafler, a globally recognized authority on multiple sclerosis whose immunological research revolutionized the management of autoimmune disorders. Hafler suspected that parallels existed between the early immunological phases of multiple sclerosis and the initial stages of Parkinson’s disease.
Supported by a grant from the Aligning Science Across Parkinson’s network, Hafler and Cedarbaum initiated a comprehensive biomarker study. They performed spinal taps on a large cohort comprising participants with RBD, established Parkinson’s disease, and dual conditions, comparing their laboratory findings against healthy control subjects and multiple sclerosis patients.
The resulting spinal fluid analyses revealed elevated white blood cell counts—a definitive marker of central nervous system inflammation—specifically within participants diagnosed with RBD. Interestingly, this acute inflammatory signature was absent in participants who had already progressed to full-scale Parkinson’s disease. Dr. Hafler notes that this trajectory mirrors the natural history of multiple sclerosis, where an initial, highly active autoimmune phase characterized by white blood cells in the spinal fluid eventually gives way to a predominantly neurodegenerative phase.
Further single-cell RNA sequencing of the spinal fluid cells allowed the team to pinpoint specific cellular populations where pro-inflammatory genes were actively transcribed. These cells functioned as receptors for tumor necrosis factor, a potent signaling protein known to drive a wide range of autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. This discovery provided concrete evidence that inflammation—particularly pathways mediated by tumor necrosis factor—plays a critical role in the earliest, pre-motor phases of Parkinson’s disease.
Intriguingly, epidemiological data has long shown that individuals suffering from systemic autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease face an elevated risk of developing Parkinson’s disease. However, patients treated with adalimumab—an antibody therapy designed to bind circulating tumor necrosis factor and block its inflammatory effects—exhibit a risk profile comparable to that of the general population. This clinical observation prompted the Yale researchers to hypothesize that adalimumab might similarly interrupt the neuroinflammatory processes fueling the early stages of Parkinson’s disease.
Dr. Ronald Postuma, a professor of neurology at McGill University and the principal investigator for the study’s Canadian operations, emphasizes the therapeutic logic of this approach. By tamping down an overactive immune response early in the disease course, clinicians hope to prevent collateral damage, stopping immune cells from mistakenly attacking vulnerable neural tissue.
What is the PRISMS study?
Formally titled "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder," or the PRISMS study, the clinical trial is coordinated through the Center for Health Technology at the University of Rochester. The trial relies on a network of 15 academic medical centers across the United States and Canada that belong to the Parkinson Study Group, a consortium with a four-decade track record of conducting clinical trials in movement disorders.
To secure enrollment, prospective candidates must undergo a polysomnography—a comprehensive sleep study—to confirm a definitive diagnosis of RBD. To maximize the certainty that alpha-synuclein pathology underlies their condition, candidates are also evaluated for hyposmia, or a diminished sense of smell. While definitive confirmation of Lewy body pathology typically requires invasive procedures like a spinal tap or skin biopsy, extensive clinical research has demonstrated that patients presenting with both RBD and an impaired sense of smell carry at least a 90% probability of harboring underlying alpha-synuclein aggregation. Consequently, meeting both criteria is mandatory for trial eligibility.
Once enrolled, participants are randomly assigned to self-administer subcutaneous injections of either adalimumab or a matching placebo every two weeks over a two-year treatment period. Throughout the trial, participants return to their clinical sites approximately nine times for comprehensive health assessments, cognitive evaluations, and standardized motor function testing. Blood samples are drawn regularly to monitor immune cell activity and track emerging protein biomarkers associated with Parkinson’s disease. Additionally, a designated subset of participants undergoes annual lumbar punctures to detect subtle molecular shifts in spinal fluid composition, including changes in alpha-synuclein aggregation.
Participants also undergo three distinct neuroimaging procedures annually. Two of these scans, including a specialized magnetic resonance imaging protocol, evaluate the structural integrity and functional capacity of the brain’s dopamine system. A third imaging modality measures regional cerebral glucose metabolism using a safe, radioactive tracer. The brains of individuals developing Parkinson’s disease exhibit distinct, abnormal patterns of energy consumption in specific anatomical regions years before motor symptoms manifest, and these metabolic alterations worsen predictably over time.
Dr. Cedarbaum explains that if the experimental treatment successfully prevents the worsening of these metabolic patterns or halts the degradation of dopamine signaling, researchers will have a tangible indicator of therapeutic efficacy.
As with any potent biologic therapy, adalimumab carries known risks and potential side effects, including an increased susceptibility to serious infections such as tuberculosis and hepatitis. The medication has also been associated with a marginally elevated risk of specific malignancies and rare neurological complications resembling demyelinating conditions. To ensure patient safety, trial coordinators maintain rigorous protocols for monitoring participants throughout the duration of the study.
While current medical interventions successfully manage the symptoms of Parkinson’s disease after onset, they remain powerless to arrest its underlying progression. The Yale-led team views the PRISMS study as a crucial paradigm shift, focusing not only on disease-modifying mechanisms but on preemptive intervention before motor impairment occurs.
Drawing comparisons to advances in multiple sclerosis care, Dr. Hafler stresses the importance of early diagnosis and prompt intervention, noting that modern therapies can halt multiple sclerosis effectively when applied in its earliest stages. The research team hopes to replicate this success in the field of movement disorders.
Funding for the PRISMS study is provided by grants from the Marcus Foundation and the National Institute on Aging. Complete details regarding the clinical trial protocol, site locations, and strict eligibility requirements are publicly available through clinicaltrials.gov and the official Yale School of Medicine research portal.
